HDAC4 and neurodegenerative disease: Because there are no selective HDAC4 inhibitors, we decided to work with NaBut, an HDAC pan-inhibitor that easily penetrates the blood–brain barrier and that has shown potential in several neurodegenerative diseases and models (Chuang et al., 2009), administered systemically.